摘要
目的：观察舒利迭吸入治疗中重度慢性阻塞性肺疾病（COPD）的临床疗效。方法：选择2013年3月～2014年3月我院收治的中重度COPD住院患者82例，随机分成2组：舒利迭组（41例）及对照组（41例）。对照组予以常规解痉、平喘、抗感染等治疗；舒利迭组则在常规组基础上加用舒利迭吸入治疗。观察两组治疗后肺功能及血气指标的改善情况。结果：舒利迭组治疗后肺功能指标 FEV1，FEV1／FVC，FEV1／预计值及血气指标PaO2、PaCO2分别为（2．65±0．22）L、（65．78±14．76）％、（69．92±15．83）％、（88．79±8．04）mmHg和（44．35± 5．12）mmHg；对照组治疗后分别为（1．68±0．25）L、（42．54±9．34）％、（54．23±12．43）％、（72．54±7．16）mm-Hg和（52．09±5．23）mmHg；治疗后两组肺功能以及血气指标比较，差异有统计学意义（P＜0．05）。结论：应用舒利迭吸入治疗中重度CPOD能改善患者肺功能，对缓解临床症状有明显作用。
Objective：To observe the clinical effects of seretide inhalation treatment of medium and severe chronic ob-structive pulmonary disease （COPD）.Methods：82 cases patients with medium and severe chronic obstructive pulmona-ry disease from march,2013 to march,2014 admitted in our hospital were collected,and randomly divided into seretide group and control group,with 41 cases in each group.The control group was treated with spasmolytic,antiasthmatic,in-fective agents,while the seretide group was given seretide inhalation on the basis of the treatment of the control group. The lung function and blood gas were observed before the treatment and three months after the treatment.Results：The lung function index FEV1 ,FEV1/FVC,FEV1/estimated value and blood gas index PaO2 ,PaCO2 of the seretide group af-ter treatment were （2.65 ±0.22）L,（65.78 ±14.76）%,（69.92 ±15.83）%,（88.79 ±8.04）mmHg and （44.35 ± 5.12）mmHg respectively;after treatment those of the control group were respectively （1.68 ±0.25）L,（42.54 ± 9.34）%,（54.23 ±12.43%）,（72.54 ±7.16）mmHg and （52.09 ±5.23）mmHg.After treatment the comparison of the lung function and blood gas index of the two groups showed that the difference was statistically significant （P〈0.05）.Conclusion：Seretide inhalation treatment can improve the lung function of the patients with medium and severe COPD,and it has obvious effect to relieve the clinical symptoms.
出处
《赣南医学院学报》
2015年第1期78-80,共3页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
关键词
舒利迭
慢性阻塞性肺疾病
肺功能
seretide
chronic obstructive pulmonary disease
lung function
